FDA Approves Unknown Drug — BARR

Barr Laboratories announced on October 14, 2004, that its Abbreviated New Drug Application for demeclocycline hydrochloride tablets was approved by the FDA, marking the approval of Atridox (Orbactiv). The greenlight allows Barr to expand its oral generic offering with this tetracycline antibiotic, likely impacting market prices for dermatologic and misused prescription treatments.